{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:18:36Z","timestamp":1777965516713,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Royal Australian and New Zealand College of Radiologists (RANZCR) Faculty of Radiation Oncology Genitourinary Group (FROGG) guidelines and online EviQ protocols incorporate prostate\u2010specific membrane antigen (PSMA) positron emission tomography (PET)\u2010guided dose\u2010escalated intensity\u2010modulated radiation therapy (DE\u2010IMRT) for newly diagnosed lymph node (LN) positive prostate cancer. We evaluated late toxicity and efficacy outcomes following the FROGG and EviQ approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with LN\u2010positive\u2010only metastases on PSMA\u2010PET imaging were offered curative therapy with 3\u2009months neoadjuvant androgen deprivation therapy (ADT) followed by DE\u2010IMRT and 3\u2009years adjuvant ADT. IMRT was delivered via volumetric arc therapy (VMAT). We aimed to deliver 81\u2009Gy in 45 fractions (Fx) to the prostate and PET\u2010positive LNs, and 60\u2009Gy in 45\u2009Fx to elective pelvic nodes, contoured using the PIVOTAL guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010five patients were included. The median number of PET\u2010positive nodes boosted was 2 (range 1\u20136) and median boost volume 1.16\u2009cc (range 0.15\u20134.14). Seventeen (38%) patients had PET\u2010positive nodes outside of PIVOTAL contouring guidelines. With 60\u2009months median follow\u2010up, disease\u2010free, metastasis\u2010free, prostate cancer\u2010specific and overall survival were 88.1%, 95.3%, 100% and 91.5%. There were no in\u2010field nodal failures. Late grade 1, 2 and 3 gastrointestinal toxicities occurred in 4%, 2% and 0% of patients, and genitourinary toxicity in 18%, 18% and 4%. Lower limb grade 2 lymphoedema occurred in three patients (7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Outcomes following FROGG guidelines and EviQ are promising, with high long\u2010term disease control and low toxicity. Contouring guidelines require modification due to the high rate of PET\u2010positive nodes demonstrated beyond recommended coverage.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.13534","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T11:15:42Z","timestamp":1682507742000},"page":"456-462","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<scp>PSMA\u2010PET<\/scp>\u2010guided dose\u2010escalated volumetric arc therapy for newly diagnosed lymph node\u2010positive prostate cancer: 5\u2009Year outcomes following the <scp>FROGG<\/scp> and <scp>EviQ<\/scp> node\u2010positive guidelines"],"prefix":"10.1111","volume":"67","author":[{"given":"Shaun Zheng Liang","family":"Yap","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Mid\u2010North Coast Cancer Institute, Coffs Harbour Health Campus  Coffs Harbour New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology North Coast Cancer Institute, Lismore Base Hospital  Lismore New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-951X","authenticated-orcid":false,"given":"Noel","family":"Aherne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Mid\u2010North Coast Cancer Institute, Coffs Harbour Health Campus  Coffs Harbour New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Philip","family":"Shakespeare","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Mid\u2010North Coast Cancer Institute, Coffs Harbour Health Campus  Coffs Harbour New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.05.016"},{"key":"e_1_2_9_3_1","unstructured":"EviQ: Cancer Institute NSW.Prostate Adenocarcinoma Definitive EBRT Prostate and Pelvic Lymph Nodes.2022. [Cited 28 May 2022.] Available from URL:https:\/\/www.eviq.org.au\/radiation\u2010oncology\/urogenital\/prostate\/3657\u2010prostate\u2010adenocarcinoma\u2010definitive\u2010ebrt\u2010prost."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.09.027"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.03.021"},{"key":"e_1_2_9_6_1","unstructured":"National Comprehensive Cancer Network.Prostate Cancer (Version 4.2022).2022. [Cited 28 May 2022.] Available from URL:https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1459."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V42N4p190"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.06.027"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4350"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv119"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.11.002"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.030"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212563"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-0983-4"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04777-z"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01660-6"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09283-z"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12224"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(84)90263-3"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02576-y"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(87)90038-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.02.011"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.04.004"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.01.062"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.06.002"},{"key":"e_1_2_9_27_1","volume-title":"Reporting for Better Cancer Outcomes (RBCO) Radiation Therapy Report, 2022","author":"Cancer Institute NSW","year":"2022"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radi.2017.01.003"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2007.01976.x"},{"key":"e_1_2_9_30_1","article-title":"Phase I\/II study of extreme hypofractionated stereotactic body radiation therapy boost to prostate for locally advanced, node\u2010positive and oligometastatic cancer","volume":"12","author":"Narang K","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_9_31_1","unstructured":"ClinicalTrials.gov.Optimal Prostate Fractionation Study.2022. [Cited 14 Nov 2022.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03386045."},{"key":"e_1_2_9_32_1","unstructured":"ClinicalTrials.gov.Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk Clinically Localised Prostate Cancer (ENZARAD).2022. [Cited 28 May 2022.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02446444."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS179"},{"key":"e_1_2_9_34_1","unstructured":"ClinicalTrials.gov.DASL\u2010HiCaP: Darolutamide Augments Standard Therapy for Localised Very High\u2010Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double\u2010blind Placebo\u2010controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk Clinically Localised Prostate Cancer.2022. [Cited 5 Jun 2022.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04136353."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.13534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:13:35Z","timestamp":1692339215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.13534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/1754-9485.13534"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.13534","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"2022-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}